Lumenis Collaborates With Urologists at the 2015 AUA Annual Meeting to Highlight the Versatility of the Pulse(TM) 120H Holmium Laser Platform

YOKNEAM, Israel, May 15, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical device company for surgical, ophthalmology, and aesthetic applications announced today that the company will host an educational symposium, in collaboration with nationally distinguished urologists, and an instructive workshop series at the American Urological Association's (AUA) 2015 Annual Meeting, being held in New Orleans, La., from May 15 – 19, 2015.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=32964

The educational symposium will feature speaker Marc Beaghler, MD, MPH, Urological Surgery & Pediatric Urology Specialist of San Buenaventura Urology Center, who will talk about Vaporization of the prostate with the Lumenis Pulse 120H and Xpeeda™ fiber, and speaker Khurshid Ghani, MBChB, Assistant Professor, Urology of the University of Michigan, who will talk about the Stone-Dusting™ technique for renal and ureteral stones.

The Lumenis Pulse 120H boasts 120 watts of optical power, and is accompanied by a range of fibers and accessories that are designed to offer optimal energy utilization, accelerated procedure time, along with a pulse reshaping technology resulting in improved hemostasis.

"I have been using the Lumenis Pulse™ 120H laser with the Xpeeda™ fiber for the treatment of BPH performing the Holmium Vaporization technique and have experienced a dramatic improvement in operative workflow," said Stephen L. Brewer, MD, FACS, Urology Department Saint Elizabeth's Healthcare System, Florence, KY. "This combination of a 120W high power laser and a fiber designed for enhanced energy delivery creates the most powerful solution for BPH. Vaporization rate, hemostasis and operative time are significantly improved. The learning curve is minimal as the technique is similar to TURP and the two foot pedal system gives the urologist an immediate sense of familiarity."

"As the gold standard treatment for BPH, Holmium Laser Enucleation of the Prostate (HoLEP) procedures have increasingly grown within the urology community in the U.S.," said Tzipi Ozer-Armon, CEO of Lumenis. "To meet the needs of a dynamic and growing market for urologic procedures in the United States the Pulse 120H platform is designed to be a superior solution also for Vaporization of the prostate, Flexible Ureteroscopy and Percutaneous Nephrolithotomy. We look forward to carrying on our collaboration with the urology community on the development of best-in-class solutions."

Lumenis will be exhibiting at booth #1317 throughout AUA. In addition to the educational symposium, the company plans to host a skills workshop series for hands-on training and instruction.

To view a schedule of the company's hosted events and to register for the symposium, please click here.

Lumenis invites AUA conference attendees to visit the Lumenis booth to explore and learn more about the company's portfolio of holmium lasers and accessories.

About Lumenis

Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. For more information visit: www.lumenis.com.

Forward-Looking Statements

Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For further information:
         Glenn Silver
         Lazar Partners Ltd.
         (646) 871-8485